The patents cover sales of Biogen products for MS that are covered by a Forward Pharma patent and have dimethyl fumarate as an active pharmaceutical ingredient. The two companies say they intend ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Biogen Inc. (NASDAQ: BIIB ... But I'm particularly happy to see in 2024 that the revenue from our launch products really offset the more than offsets the decline in our multiple sclerosis product ...

although its hard to avoid the conclusion that Biogen embodies most of what the public - and Wall Street - dislike most about Big Pharma. Bad, overpriced products, endless study failures ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

Biogen has received an option to license rights to certain future antisense oligonucleotide products targeting ... originally created and published by Pharmaceutical Technology, a GlobalData ...

The stock's fall snapped a seven-day winning streak.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.